We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Personal Continuous Glucose Monitoring Device Validated

By LabMedica International staff writers
Posted on 17 Sep 2008
A personal continuous glucose-monitoring (CGM) device significantly reduced the average blood glucose levels (A1c) of adult patients with type 1 diabetes. More...
This further validated the ability of the device to substantially improve diabetes management and glucose control. Reducing A1c can result in reduced risk of long-term side effects associated with diabetes, including blindness and kidney disease.

A multicenter, 322-patient trial, funded by the Juvenile Diabetes Research Foundation (JDRF; New York, NY, USA), found that after six months adults using the personal CGM realized a statistically significant 0.53% absolute reduction in A1c as compared to the control group. All patients in the study experienced statistically significant absolute reductions in A1c levels ranging from 0.5-0.7% when the personal CGM was used at least six days a week. Moreover, improvements in A1c occurred without an increase in severe hypoglycemia (low blood sugar).

Medtronic (Northridge, CA, USA) currently markets the integrated diabetes management system that combines the personal CGM with insulin pump therapy. It is called the MiniMed Paradigm Real-Time system. Medtronic also offers a stand-alone personal CGM device--the Guardian Real-Time system.

Medtronic is a world leader in advanced diabetes management solutions. Their products include integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems, and therapy management software.

"We are confident that the JDRF study results will aid physicians' efforts to bring personal CGM to more patients,” said Chris O'Connell, president of the diabetes business at Medtronic. "In fact, healthcare insurers are already seeing value in this technology. Many have policies for personal CGM devices, and new coverage decisions are being made regularly.”

Results from the multicenter study were presented on September 8, 2008, during the European Association for the Study of Diabetes annual meeting in Rome, Italy, and portions of the data will be published in the October 2, 2008, issue of the New England Journal of Medicine, which is also available online.

Related Links:
Juvenile Diabetes Research Foundation
Medtronics


New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Portable Electronic Pipette
Mini 96
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Elecsys Dengue Ag assay is intended for the in vitro qualitative detection of dengue virus NS1 antigen in human serum and plasma (Photo courtesy of Roche)

Automated Test Distinguishes Dengue from Acute Fever-Causing Illnesses In 18 Minutes

Dengue fever remains the most common mosquito-borne viral infection worldwide, posing a major public health challenge as global cases continue to surge. In 2024 alone, more than 14.6 million infections... Read more

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.